Group 1 - The core point of the article is that Saifen Technology (SH 688758) announced that approximately 256 million restricted shares will be unlocked and listed for trading on January 12, 2026, which accounts for 61.4% of the company's total share capital [1] - As of the report, Saifen Technology has a market capitalization of 7.5 billion yuan [1] - The revenue composition for Saifen Technology for the year 2024 is as follows: drug analysis 40.2%, antibody drugs 20.85%, insulin/peptide/GLP-1 18.18%, recombinant proteins 13.73%, and others 6.6% [1] Group 2 - The article also highlights a significant event at the Moutai distributor conference, where over 2,000 attendees gathered to discuss major changes regarding Moutai's pricing and distribution strategies [1] - Chairman Chen Hua emphasized that distributors can no longer rely on passive income [1]

Group 1 - Core technical personnel Yang Ke has officially retired due to reaching the legal retirement age and will no longer hold any position in the company [1] - As of the report, the market capitalization of the company is 7.7 billion yuan [1] Group 2 - For the fiscal year 2024, the revenue composition of the company is as follows: drug analysis accounts for 40.2%, antibody drugs for 20.85%, insulin/peptide/GLP-1 for 18.18%, recombinant proteins for 13.73%, and others for 6.6% [1]